Black Diamond Therapeutics, INC Form 4 insider transactions

Elizabeth Buck, Chief Scientific Officer of Black Diamond Therapeutics, was granted stock options and restricted stock units (RSUs) on January 30, 2025.

Erika Jones, a Senior Vice President at Black Diamond Therapeutics, reported the acquisition of restricted stock units and stock options.

Brent Hatzis-Schoch, Chief Operating Officer and General Counsel of Black Diamond Therapeutics, received stock options and restricted stock units (RSUs) as part of the company's 2020 Stock Option and Incentive Plan.

A Black Diamond Therapeutics director, Ali Behbahani, acquired 5,750 shares of common stock in lieu of cash compensation and disposed of 63,334 shares, while indirectly holding 4,448,757 shares through related entities.

A Black Diamond Therapeutics director, Prakash Raman, acquired 5,150 shares of common stock in lieu of cash compensation and disposed of 10,145 shares.

Director Shannon Campbell of Black Diamond Therapeutics acquired 4,500 shares of common stock in lieu of cash compensation and disposed of 8,865 shares.

Director Ali Behbahani acquired 3,007 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services.

Director Shannon Campbell acquired and disposed of Black Diamond Therapeutics (BDTX) common stock on September 20, 2024, according to a Form 4 filing.

Director Prakash Raman acquired 2,694 shares and disposed of 4,995 shares of Black Diamond Therapeutics common stock on September 20, 2024.

Versant Venture Capital VI, L.P. reports the sale of 221,600 shares of Black Diamond Therapeutics, Inc. at an average price of $6.3202 per share.

Director Ali Behbahani acquired 2,887 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services as a non-employee director.

Director Prakash Raman acquired and disposed of 2,301 shares of Black Diamond Therapeutics common stock on June 21, 2024, as part of the company's non-employee director compensation policy.

Director Shannon Campbell acquired and disposed of shares of Black Diamond Therapeutics common stock on June 21, 2024, as part of the company's non-employee director compensation policy.

Director Ali Behbahani acquired 30,550 stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.

Director Samarth Kulkarni acquired 30,550 stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.

Director Garry E. Menzel acquired stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.

Director Prakash Raman acquires 30,550 stock options in Black Diamond Therapeutics.

Director Shannon Campbell acquired 30,550 stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.

Director Kapil Dhingra acquired 30,550 stock options in Black Diamond Therapeutics on June 6, 2024.

Director Shannon Campbell acquired stock options in Black Diamond Therapeutics, Inc. on April 10, 2024.

Director Prakash Raman acquires 61,100 stock options in Black Diamond Therapeutics.

Director Ali Behbahani acquired 3,166 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services as a non-employee director.

Director Wendy L. Dixon acquired 3,253 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services as a non-employee director.